Emergent BioSolutions Inc. — Director's Dealing 2017

Mar 10, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Emergent BioSolutions Inc. (EBS)
CIK: 0001367644
Period of Report: 2017-03-09

Reporting Person: El-Hibri Fuad (Director, Chairman, 10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2017-03-09	Common Stock	M	13236	—	Acquired	1669372	Direct
2017-03-09	Common Stock	F	3621	$30.98	Disposed	1665751	Direct
2017-03-10	Common Stock	M	20554	—	Acquired	1686305	Direct
2017-03-10	Common Stock	F	6089	$31.05	Disposed	1680216	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-03-09	Restrictive Stock Units	$	M	13236	Disposed		Common Stock (13236)	Direct
2017-03-10	Restrictive Stock Units	$	M	20554	Disposed		Common Stock (20554)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	4344250	Indirect
Common Stock	1524155	Indirect

Footnotes

F1: Restricted stock units convert into common stock on a one-for-one basis.

F2: Mr. El-Hibri's wife, individually, and Mr. and Mrs. El-Hibri, as tenants by the entirety, collectively hold an aggregate 40.65% equity interest in Intervac, L.L.C., which in turn is the direct owner of 4,344,250 shares of the Issuer's common stock. Mr. El-Hibri disclaims beneficial ownership of the shares of the Issuer's common stock directly owned by Intervac, L.L.C. for purposes of Section 16 of the Exchange act or otherwise, except to the extent of his pecuniary interest therein.

F3: Mr. El-Hibri holds individually and with his wife, as tenants by the entirety, an aggregate 89.2% equity interest in Biovac, LLC, which in turn is the direct owner of 1,524,155 shares of the Issuer's common stock. Mr. El-Hibri disclaims beneficial ownership of the shares of the Issuer's common stock directly owned by Biovac, LLC for purposes of Section 16 of the Exchange act or otherwise, except to the extent of his pecuniary interest therein.

F4: In connection with the Issuer's spin-off of Aptevo Therapeutics Inc. effective on August 1, 2016 (the "Spin-off"), the Issuer made certain adjustments to the price and number of equity awards held by the Issuer's continuing employees. Accordingly, Mr. El-Hibri received an equitable adjustment to the number and grant price of his restricted stock units.

F5: On March 10, 2015, Mr. El-Hibri was granted 39,709 restricted stock units (after giving effect to the adjustment in connection with the Spin-off) vesting in three equal annual installments beginning on the day prior to the anniversary of the grant date.

F6: On March 11, 2014, Mr. El-Hibri was granted 61,622 restricted stock units (after giving effect to the adjustment in connection with the Spin-off) vesting in three equal annual installments beginning on the day prior to the anniversary of the grant date.